Skip to main content
Top
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | Metastasis | Original Article

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

Authors: Z. Burián, A. Ladányi, T. Barbai, V. Piurkó, T. Garay, E. Rásó, József Tímár

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Zinc as an essential trace metal is a ubiquitous component of various molecules of the cell. Studies indicated that it may modulate functions of various cancer cell types, and can even inhibit metastasis formation in experimental models. In melanoma, zinc was shown to affect melanin production and to induce apoptosis. Using human melanoma cell lines, we have tested the effects of ZnSO4 on cell proliferation, survival, migration as well as in vivo on experimental liver colony formation. We have found that ZnSO4 has antiproliferative and proapoptotic effects in vitro. In SCID mice intraperitoneal administration of ZnSO4 specifically inhibited liver colony formation without affecting primary tumor growth. To reveal the molecular mechanisms of action of zinc in human melanoma, we have tested mRNA expression of zinc finger transcription factors and found a strong inhibitory effect on HIF1α, as compared to WT1 whereas HIF2α and MTF1 expression was unaffected. Immunohistochemical detection of HIF1α protein in liver metastases confirmed its decreased nuclear expression after in vivo ZnSO4 treatment. These data indicate that in human melanoma zinc administration may have an antimetastatic effect due to a selective downregulation of HIF1α.
Literature
1.
go back to reference Vallee BL, Falchuk KH (1993) The biochemical basis of zinc physiology. Phys Rev 73:79–118 Vallee BL, Falchuk KH (1993) The biochemical basis of zinc physiology. Phys Rev 73:79–118
2.
go back to reference Grattan BJ, Freake HC (2012) Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients 4:648–675CrossRef Grattan BJ, Freake HC (2012) Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients 4:648–675CrossRef
3.
go back to reference Intsuka S, Araki S (1978) Plasma copper and zinc levels in patients with malignant tumors of digestive organs: clinical evaluation of the cu/Zn ratio. Cancer 42:626–631CrossRef Intsuka S, Araki S (1978) Plasma copper and zinc levels in patients with malignant tumors of digestive organs: clinical evaluation of the cu/Zn ratio. Cancer 42:626–631CrossRef
4.
go back to reference Hisaki T, Furumoto T, Nozaka K, Koga S (1988) Serum zinc and copper changes after gastrectomy in aged patients with gastric cancer. Jpn J Sur 18:158–163CrossRef Hisaki T, Furumoto T, Nozaka K, Koga S (1988) Serum zinc and copper changes after gastrectomy in aged patients with gastric cancer. Jpn J Sur 18:158–163CrossRef
5.
go back to reference Prasad AS, Beck FW, Doerr TD, Shamsa FH, Mathog RH (1998) Nutritional and zinc status of head and neck cancer patients: an interpretive review. Am Coll Nutr 17:409–418CrossRef Prasad AS, Beck FW, Doerr TD, Shamsa FH, Mathog RH (1998) Nutritional and zinc status of head and neck cancer patients: an interpretive review. Am Coll Nutr 17:409–418CrossRef
6.
go back to reference Yucel I, Arpaci F, Ozet A, Berk O (1994) Serum copper and zinc levels and copper/zinc ratio in patients with breast cancer. Biol Trace Elem Res 40:31–38CrossRef Yucel I, Arpaci F, Ozet A, Berk O (1994) Serum copper and zinc levels and copper/zinc ratio in patients with breast cancer. Biol Trace Elem Res 40:31–38CrossRef
7.
go back to reference Igic PG, Lee E, Harper W, Roach KW (2012) Toxic effects associated with consumption of zinc. Mayo Clin Proc 77:713–716CrossRef Igic PG, Lee E, Harper W, Roach KW (2012) Toxic effects associated with consumption of zinc. Mayo Clin Proc 77:713–716CrossRef
9.
go back to reference Timar J, Raso R, Paku S, Kopper L (1998) Oral administration of a trace element preparation and zinc inhibit liver metastasis of 3LL-HH murine tumor cells. Int J Mol Med 2:105–113PubMed Timar J, Raso R, Paku S, Kopper L (1998) Oral administration of a trace element preparation and zinc inhibit liver metastasis of 3LL-HH murine tumor cells. Int J Mol Med 2:105–113PubMed
10.
go back to reference Dubi N, Gheber L, Fisgman D, Sekler I, Hershfinkel M (2008) Extracellular zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells. Carcinogenesis 29:1692–1702CrossRef Dubi N, Gheber L, Fisgman D, Sekler I, Hershfinkel M (2008) Extracellular zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells. Carcinogenesis 29:1692–1702CrossRef
11.
go back to reference Hwang JJ, Kim HN, Kim J, Cho DH, Kim MJ, Kim YS, Kim Y, Park SJ, Koh JY (2010) Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 23(6):997–1013CrossRef Hwang JJ, Kim HN, Kim J, Cho DH, Kim MJ, Kim YS, Kim Y, Park SJ, Koh JY (2010) Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 23(6):997–1013CrossRef
12.
go back to reference Yamada H, Suzuki K, Koizumi S (2007) Gene expression profile in human cells exposed to zinc. J Toxicol Sci 32:193–196CrossRef Yamada H, Suzuki K, Koizumi S (2007) Gene expression profile in human cells exposed to zinc. J Toxicol Sci 32:193–196CrossRef
13.
go back to reference Kindermann B, Döring F, Pfaffl M, Daniel H (2004) Identification of genes responsive to intracellular zinc depletion in the human colon adenocarcinoma cell line HT-29. J Nutr 134:57–62CrossRef Kindermann B, Döring F, Pfaffl M, Daniel H (2004) Identification of genes responsive to intracellular zinc depletion in the human colon adenocarcinoma cell line HT-29. J Nutr 134:57–62CrossRef
14.
go back to reference Schadendorf D, vanAkkoi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A et al (2018) Melanoma. Lancet 392:971–984CrossRef Schadendorf D, vanAkkoi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A et al (2018) Melanoma. Lancet 392:971–984CrossRef
15.
go back to reference Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr. (2003) Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 16:273–279CrossRef Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr. (2003) Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res 16:273–279CrossRef
16.
go back to reference Ladányi A, Tímár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461CrossRef Ladányi A, Tímár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461CrossRef
17.
go back to reference Timár J, Rásó E, Honn KV, Hagmann W (1999) 12-lipoxygenase expression in human melanoma cell lines. Adv Exp Med Biol 469:617–622CrossRef Timár J, Rásó E, Honn KV, Hagmann W (1999) 12-lipoxygenase expression in human melanoma cell lines. Adv Exp Med Biol 469:617–622CrossRef
18.
go back to reference Garay, T., E. Juhasz, E. Molnar, M. Eisenbauer, A. Czirok, B. Dekan,et al. (2013) Cell migration or cytokinesis and proliferation? - revisiting the "go or grow" hypothesis in cancer cells in vitro. Exp Cell Res 319:3094–3103CrossRef Garay, T., E. Juhasz, E. Molnar, M. Eisenbauer, A. Czirok, B. Dekan,et al. (2013) Cell migration or cytokinesis and proliferation? - revisiting the "go or grow" hypothesis in cancer cells in vitro. Exp Cell Res 319:3094–3103CrossRef
19.
go back to reference Wellinghausen N, Kirchner H, Rink L (1997) The immunobiology of zinc. Immunol Today 18:523–524CrossRef Wellinghausen N, Kirchner H, Rink L (1997) The immunobiology of zinc. Immunol Today 18:523–524CrossRef
20.
go back to reference Franklin RB, Costello LC (2009) The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 106:750–757CrossRef Franklin RB, Costello LC (2009) The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 106:750–757CrossRef
21.
go back to reference Kim I, Kim CH, Seo GH, Kim HS, Lee J, Kim DG, Ahn YS (2008) Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport 19:1065–1068 Kim I, Kim CH, Seo GH, Kim HS, Lee J, Kim DG, Ahn YS (2008) Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport 19:1065–1068
22.
go back to reference Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G (2010) Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One 5:e15048CrossRef Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D'Orazi G (2010) Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One 5:e15048CrossRef
23.
go back to reference Yuan Y, Hillind G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia inducible factor-a and von Hippel Lindau protein by direct binding to hypoxia inducible factor-a. J Biol Chem 278:15911–15916CrossRef Yuan Y, Hillind G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia inducible factor-a and von Hippel Lindau protein by direct binding to hypoxia inducible factor-a. J Biol Chem 278:15911–15916CrossRef
24.
go back to reference Chun YS, Choi E, Yeo EJ, Lee HJ, Kim MS, Park JW (2001) A new HIF1 alpha variant induced by zinc ion suppresses HIF1-mediated hypoxic responses. J Cell Sci 114:4051–4061PubMed Chun YS, Choi E, Yeo EJ, Lee HJ, Kim MS, Park JW (2001) A new HIF1 alpha variant induced by zinc ion suppresses HIF1-mediated hypoxic responses. J Cell Sci 114:4051–4061PubMed
25.
go back to reference Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G (2009) Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF1-alpha. PlosOne 4:e6819CrossRef Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G (2009) Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF1-alpha. PlosOne 4:e6819CrossRef
26.
go back to reference Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46:1159–1169CrossRef Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46:1159–1169CrossRef
27.
go back to reference Zbytek B, Peacock DL, Seagroves TN, Slominski A (2013) Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 5:239–251CrossRef Zbytek B, Peacock DL, Seagroves TN, Slominski A (2013) Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 5:239–251CrossRef
28.
go back to reference Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H (2009) Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34:e962–e964CrossRef Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H (2009) Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34:e962–e964CrossRef
29.
go back to reference Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O’Brien ET III, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY (2013) HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078–2093CrossRef Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O’Brien ET III, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY (2013) HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 123:2078–2093CrossRef
30.
go back to reference Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, Tóvári J (2017) Cell-type dependent HIF1α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8:44498–44510CrossRef Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, Tóvári J (2017) Cell-type dependent HIF1α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8:44498–44510CrossRef
31.
go back to reference Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525CrossRef Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525CrossRef
32.
go back to reference Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271–276CrossRef Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271–276CrossRef
Metadata
Title
Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma
Authors
Z. Burián
A. Ladányi
T. Barbai
V. Piurkó
T. Garay
E. Rásó
József Tímár
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-00573-1

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine